Cost-effectiveness of pneumococcal conjugate vaccination in Croatia

Highlights • PCV is not cost-effective in Croatia based on benefits in children alone. • PCV could prevent ∼100 hospital admissions for children

Saved in:
Bibliographic Details
Published in:Vaccine 2015-05, Vol.33, p.A209-A218
Main Authors: Vučina, V. Višekruna, Filipović, S. Kurečić, Kožnjak, N, Stamenić, V, Clark, A.D, Mounaud, B, Blau, J, Hoestlandt, C, Kaić, B
Format: Article
Language:English
Subjects:
Allergy and Immunology
Child, Preschool
Cost control
Cost-Benefit Analysis
Cost-effectiveness
Croatia
Croatia - epidemiology
Decision-making
Demography
Ear diseases
Economics
Evidence-based medicine
Health care
Health Policy
Health services
Humans
Immunization
Immunization Programs
Infant
Infant, Newborn
Life expectancy
Models, Statistical
Mortality
Pneumococcal
Pneumococcal Infections - economics
Pneumococcal Infections - epidemiology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - economics
Pneumococcal Vaccines - immunology
Price cuts
Public health
Sensitivity analysis
Streptococcus pneumoniae
Vaccination - economics
Vaccination - methods
Vaccine
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • PCV is not cost-effective in Croatia based on benefits in children alone. • PCV could prevent ∼100 hospital admissions for children
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.12.043